Nantes

• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• Phase 3 Trial of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation Recruiting
  2022-503012-16-00 5 2022-07-20 Patients on treatment with Factor Xa Inhibitor needing for an urgent i
• A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab. Recruiting
  2024-513185-19-00 9 2022-07-13 Extensive stage small cell lung cancer (ES-SCLC)
• A phase II study evaluating the efficacy of Selective Internal Radiation Therapy combined with Capecitabine in the neoadjuvant setting of Op … Recruiting
  2024-516683-29-00 4 2022-02-04 Biliary tract cancer
• A Phase 1/2 Study of Bleximenib in Participants with Acute Leukemia Recruiting
  2023-506581-31-00 1 2021-06-15 Acute Leukemia
• Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and the … Recruiting
  2022-501677-39-00 5 2021-05-25 Adolescent Renal Allografts
• A Phase 1/2 First in Human Study of the Menin-MLL (KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia Recruiting
  2023-510509-17-00 7 2020-06-17 Relapsed and/or refractory Acute Myeloid Leukemia
• A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zos … Recruiting
  2022-502784-37-00 4 2019-09-03 Prevention of Herpes Zoster in immunocompromised subjects aged 1-17 ye
• A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso … Recruiting
  2024-511855-16-00 5 2019-07-25 Onco-hematology
• Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in … Recruiting
  2024-516807-17-00 4 2019-01-02 Relapsing/Refractory ALK+ Anaplastic Large cell Lymphoma
• Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia Recruiting
  2023-504694-20-00 9 2017-01-13 pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukem
• STARS (Secukinumab in TAkayasu ARteritiS) Recruiting
  2024-516215-24-00 4 2026-07-01 TAkayasu ARteritiS
• An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients wi … Recruiting
  2025-524367-20-00 4 2026-06-30 Adult patients with primary mitochondrial disease
• Study of an On-Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis Recruiting
  2025-523726-40-00 5 2026-06-24 Multiple Sclerosis
• ERPPAD - Efficacy in Relapse Prevention: Psilocybin in Alcohol use disorder with Depressive symptoms Recruiting
  2025-525069-65-00 5 2026-06-24 Alcohol use disorder
• LIDOCRIT : Effect of continuous intravenous LIDOCaine on discomfort in postoperative CRITical care inpatients Recruiting
  2024-517749-15-00 11 2026-06-12 Postoperative critical care
• Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter ran … Recruiting
  2024-518018-22-00 5 2026-06-11 staphylococcal endocarditis
• OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE Recruiting
  2025-524573-16-00 6 2026-06-11 Crohn's disease
• A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu … Recruiting
  2025-521587-35-00 5 2026-06-03 Metastatic colorectal cancer
• Efficacy, Safety, and Tolerability of DYNE-101 in Participants with Myotonic Dystrophy Type 1 Recruiting
  2025-522957-20-00 5 2026-05-29 Myotonic Dystrophy Type 1
• A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-522007-18-00 5 2026-05-27 Relapsed or Refractory Multiple Myeloma
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis

Showing 145–168 of 800 trials